Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

China flag China · Delayed Price · Currency is CNY
13.21
-0.19 (-1.42%)
Aug 14, 2025, 2:45 PM CST
29.76%
Market Cap 17.75B
Revenue (ttm) 5.28B
Net Income (ttm) 648.29M
Shares Out 1.47B
EPS (ttm) 0.44
PE Ratio 29.90
Forward PE 22.87
Dividend 0.25 (1.87%)
Ex-Dividend Date Jul 7, 2025
Volume 6,466,920
Average Volume 11,613,201
Open 12.93
Previous Close 13.40
Day's Range 12.93 - 13.49
52-Week Range 9.01 - 14.34
Beta 0.41
RSI 59.95
Earnings Date Aug 30, 2025

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products, such as prolongin, inhixa, neoparin, and heparin and enoxaparin sodium injections; API products, including heparin and enoxaparin sodium APIs; and pan... [Read more]

Sector Healthcare
Founded 1998
Employees 1,926
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002399
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.